Can Fite Biopharma LtdNYSE American:CANF
No Matches were found for
- LAST PRICE2.1100
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots2.0200/ 20
- Ask / Lots2.3300/ 20
- Open / Previous Close--- / 2.1100
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
Select an index
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CANF |
|---|---|---|
| 09:32 ET | 4600 | 2.05 |
| 09:35 ET | 939 | 2.08 |
| 09:42 ET | 1150 | 2.08 |
| 09:48 ET | 1000 | 2.105 |
| 09:55 ET | 1533 | 2.07 |
| 10:02 ET | 9520 | 2.0853 |
| 10:06 ET | 2715 | 2.08 |
| 10:08 ET | 300 | 2.08 |
| 10:09 ET | 1500 | 2.09 |
| 10:11 ET | 1420 | 2.1 |
| 10:22 ET | 300 | 2.1151 |
| 10:27 ET | 1452 | 2.12 |
| 10:36 ET | 600 | 2.14 |
| 10:38 ET | 900 | 2.1427 |
| 10:44 ET | 100 | 2.12 |
| 10:49 ET | 30061 | 1.99 |
| 11:21 ET | 850 | 2.05 |
| 11:25 ET | 250 | 2.03 |
| 11:27 ET | 200 | 2.05 |
| 11:30 ET | 250 | 2.05 |
| 11:36 ET | 500 | 2.05 |
| 11:39 ET | 2010 | 2.01 |
| 11:41 ET | 1000 | 2.0599 |
| 11:43 ET | 530 | 2.0101 |
| 11:59 ET | 200 | 2.04 |
| 12:03 ET | 500 | 2.0599 |
| 12:28 ET | 100 | 2.02 |
| 12:51 ET | 400 | 2.02 |
| 12:53 ET | 100 | 2.02 |
| 12:57 ET | 159 | 2.0209 |
| 01:09 ET | 100 | 2.05 |
| 01:20 ET | 200 | 2.05 |
| 01:27 ET | 100 | 2.04 |
| 01:38 ET | 200 | 2.05 |
| 01:40 ET | 200 | 2.05 |
| 02:07 ET | 1481 | 2.1164 |
| 02:30 ET | 900 | 2.0939 |
| 02:43 ET | 6620 | 2.02 |
| 02:54 ET | 110 | 2.06 |
| 03:03 ET | 200 | 2.055 |
| 03:12 ET | 5403 | 2 |
| 03:33 ET | 100 | 2.01 |
| 03:42 ET | 200 | 2.04 |
| 03:44 ET | 300 | 2.05 |
| 03:46 ET | 2100 | 2.06 |
| 04:00 ET | 1002 | 2.11 |
Nov 22, 2024
Nov 12, 2024
DJ Can-Fite Biopharma Price Target Maintained With a $18.00/Share by HC Wainwright & Co., from 7:03AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:03AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 11, 2024
Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical Trial, from 7:00AM ET on Monday Nov 11, 2024 by Dow Jones
7:00AM ET on Monday Nov 11, 2024 by Dow Jones
Nov 4, 2024
Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in Australia, from 7:08AM ET on Monday Nov 04, 2024 by Dow Jones
7:08AM ET on Monday Nov 04, 2024 by Dow Jones
Company Information
No data available
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | --- |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | --- |
Can Fite Biopharma Ltd does not pay a dividend. | |
Beta | --- |
EPS | --- |
Book Value | --- |
P/E Ratio | --- |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
